Overview
Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat. The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.
Indication
The use of diet supplements containing taurine is indicated for the nutritional support of infants and young pediatric patients requiring total parenteral nutrition via central or peripheral routes. The usage of diet supplements containing taurine prevents nitrogen and weight loss or to treat negative nitrogen balance in pediatric patients where the alimentary tract cannot be done through oral, gastrostomy or jejunostomy administration, there is impaired gastrointestinal absorption or protein requirements are substantially increased.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/19 | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | ||
2024/12/06 | Phase 2 | Not yet recruiting | |||
2024/10/15 | Phase 1 | Active, not recruiting | |||
2021/05/05 | Phase 2 | Recruiting | |||
2021/02/26 | Not Applicable | Completed | Maharishi Markendeswar University (Deemed to be University) | ||
2019/04/08 | Phase 2 | Completed | |||
2018/01/25 | Not Applicable | UNKNOWN | |||
2018/01/25 | Not Applicable | UNKNOWN | |||
2015/08/28 | Phase 4 | Completed | Riyadh Colleges of Dentistry and Pharmacy | ||
2013/03/22 | Phase 3 | Completed | Zhiming Zhu |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Baxter Healthcare Corporation | 0338-1131 | INTRAVENOUS | 15 mg in 100 mL | 8/4/2022 | |
| B. Braun Medical Inc. | 0264-1933 | INTRAVENOUS | 0.025 g in 100 mL | 8/22/2022 | |
| Bispit Canada Ltd. | 85631-004 | ORAL | 30 mg in 1.2 g | 8/3/2025 | |
| ICU Medical Inc. | 0990-4178 | INTRAVENOUS | 50 mg in 100 mL | 9/21/2021 | |
| Baxter Healthcare Corporation | 0338-1130 | INTRAVENOUS | 25 mg in 100 mL | 8/4/2022 | |
| ICU Medical Inc. | 0990-4179 | INTRAVENOUS | 70 mg in 100 mL | 7/19/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| SmofKabiven Emulsion for Infusion | SIN14286P | INJECTION, EMULSION | 1.0g /1000ml | 1/8/2013 | |
| SmofKabiven Electrolyte Free Emulsion for Infusion | SIN14292P | INJECTION, EMULSION | 1.0g /1000ml | 1/16/2013 | |
| TROPHAMINE INJECTION 10% | SIN07846P | INJECTION | 0.025 g/100 ml | 9/12/1994 | |
| SmofKabiven Peripheral Emulsion for Infusion | SIN14287P | INJECTION, EMULSION | 1.0g /1000ml | 1/8/2013 | |
| SMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION | SIN16136P | INJECTION, EMULSION | 0.65g/1000ml | 3/24/2021 | |
| VAMINOLACT INTRAVENOUS SOLUTION | SIN07428P | INJECTION | 300 mg/1000 ml | 5/12/1993 | |
| AMINOVEN SOLUTION FOR INFUSION 15% | SIN16337P | INFUSION, SOLUTION | 2g/L | 9/30/2021 | |
| AMINOVEN SOLUTION FOR INFUSION 10% | SIN11829P | INJECTION | 1.000 g/1000 ml | 2/28/2002 | |
| PRIMENE 10% AMINO ACID INTRAVENOUS INFUSION | SIN10252P | INJECTION | 0.6 g/l | 9/23/1998 | |
| AMINOVEN SOLUTION FOR INFUSION 5% | SIN11682P | INJECTION | 0.500 g/1000 ml | 9/25/2001 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| VAMINOLACT I.V. SOLUTION | N/A | N/A | N/A | 10/14/1992 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| AMINOVEN amino acid 10% solution for infusion 500 mL bottle | 117659 | Medicine | A | 10/22/2007 | |
| Digestive Zyme | 328366 | Interclinical Laboratories Pty Ltd | Medicine | A | 1/8/2020 |
| SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL | 180546 | Medicine | A | 1/9/2012 | |
| Mediherb P2-Detox | 218993 | Medicine | A | 1/8/2014 | |
| NUTRA-LIFE BILBERRY 10,000 PLUS | 310442 | Medicine | A | 10/17/2018 | |
| MUSASHI SLEEP RECOVERY | 308710 | Medicine | A | 8/28/2018 | |
| Ultra Muscleze Forest Berries | 305454 | Medicine | A | 6/27/2018 | |
| METAGENICS FIBROPLEX PLUS ORANGE | 350478 | Medicine | A | 12/2/2020 | |
| Swisse Ultivite Women's High Potency Multivitamin | 369430 | Medicine | A | 6/16/2021 | |
| EZZ FEM Immune Support | 447973 | Medicine | A | 5/7/2024 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| AMINOSYN-PF 10% | hospira healthcare ulc | 00731366 | Solution - Intravenous | 70 MG / 100 ML | 12/31/1990 |
| PRIMENE 10%-LIQ IV | clintec nutrition company | 02161192 | Liquid - Intravenous | 60 MG / 100 ML | 12/31/1995 |
| PRIMENE 10% | baxter corporation | 02236875 | Liquid - Intravenous | 60 MG / 100 ML | 11/14/1997 |
| ESSEPNA | fresenius kabi canada ltd | 02510324 | Solution - Intravenous | 0.1 G / 100 ML | 1/25/2023 |
| SMOFKABIVEN EXTRA NITROGEN ELECTROLYTE FREE | fresenius kabi canada ltd | 02501775 | Emulsion - Intravenous | 0.65 G / 100 ML | 7/9/2021 |
| SMOFKABIVEN PERIPHERAL | fresenius kabi canada ltd | 02456206 | Emulsion - Intravenous | 32 MG / 100 ML | 2/14/2017 |
| AMINOSYN-PF 7% | hospira healthcare ulc | 00731358 | Solution - Intravenous | 50 MG / 100 ML | 12/31/1990 |
| SMOFKABIVEN | fresenius kabi canada ltd | 02440695 | Emulsion - Intravenous | 0.05 G / 100 ML | 9/15/2015 |
| ESSENTIALS PLUS - TAB | alive international | 02229851 | Tablet - Oral | 0.5 MG | 1/28/1997 |
| SMOFKABIVEN EXTRA NITROGEN | fresenius kabi canada ltd | 02501813 | Emulsion - Intravenous | 0.065 G / 100 ML | 5/5/2021 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.